The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

If you sized SANA small after the May post, the thesis is tracking; consider letting winners run while watching for pullbacks ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

United States Insulin Pens Market Size, Insights, and Forecast Report 2025-2033, Competitive Analysis of Eli Lilly, Sanofi, Glooko, Medtronic, Novo Nordisk, and Owen Mumford - ResearchAndMarkets.com ...

The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate intervention. In April 2025, ...

Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘ACCLAIM-Lp (a)’ to evaluate the efficacy of Lepodisiran in reducing major adverse cardiovascular events in adults ...

Long-lasting insulin takes another step forward with latest clinical trial results Scripps researcher delivers findings for Lilly drug expected to request approval from FDA soon ...

Listen to This Article US-based pharmaceutical company Eli Lilly on Monday announced findings from the Phase 3 clinical trials for its once-weekly investigational insulin drug, efsitora alfa (efsitora ...

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA approval is expected in 2026.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...